URGN Live signaler | Maksimer profitt med Getagraph.com

SELG 108914 min ago

@ $19.19

Utstedt: 13 feb 2024 @ 17:02

Avkastning: -26.27%

Forrige signal: feb 12 - 21:11

Forrige signal: Kjøp

Avkastning: -0.20 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases...

Stats
Dagens volum	135 619
Gjennomsnittsvolum	364 868
Markedsverdi	482.83M
EPS	$0 ( 2024-03-21 )
Neste inntjeningsdato	( $-0.930 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.99
ATR14	$0.0290 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Schoenberg Mark	Sell	12 000	Ordinary Shares
2024-01-31	Kim Dong	Buy	3 333	Ordinary Shares
2022-03-25	Kim Dong	Buy	20 000	Stock Option (right to buy)
2024-02-01	Smith Jason Drew	Sell	3 328	Ordinary Shares
2024-02-01	Smith Jason Drew	Sell	1 248	Ordinary Shares

INSIDER POWER
58.85
Last 96 transactions
Buy: 1 308 776 \| Sell: 407 960

Volum Korrelasjon

Lang: 0.26 (neutral)

Kort: -0.02 (neutral)

Signal:(62.511) Neutral

Urogen Pharma Ltd Korrelasjon

10 Mest positive korrelasjoner
SVAC	0.916
GOODM	0.907
TLGT	0.891
MTSL	0.871
NSTS	0.866
TTWO	0.86
LUNG	0.851
PAIC	0.851
RMNI	0.845
RCM	0.833

10 Mest negative korrelasjoner
LWAC	-0.955
SRAC	-0.919
AMRB	-0.902
LMRKN	-0.889
NETE	-0.881
KNSA	-0.847
UTHR	-0.847
RAVN	-0.84
OFS	-0.831
TECH	-0.828

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Urogen Pharma Ltd Korrelasjon - Valuta/Råvare

-0.37
( neutral )

-0.51
( weak negative )

0.00
( neutral )

-0.54
( weak negative )

0.05
( neutral )

-0.06
( neutral )

Urogen Pharma Ltd Økonomi

Annual	2023
Omsetning:	$82.71M
Bruttogevinst:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2023
Omsetning:	$82.71M
Bruttogevinst:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2022
Omsetning:	$64.36M
Bruttogevinst:	$56.70M (88.11 %)
EPS:	$-4.79

FY	2021
Omsetning:	$48.04M
Bruttogevinst:	$42.89M (89.27 %)
EPS:	$-4.96

Financial Reports:

No articles found.

Urogen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.